These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 19024375)

  • 21. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
    Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
    Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage intensity modulated radiotherapy using endorectal balloon after radical prostatectomy: clinical outcomes.
    Ishiyama H; Teh BS; Blanco AI; Paulino AC; Mai WY; Caillouet J; Xu B; Butler EB
    Int J Urol; 2013 Dec; 20(12):1178-83. PubMed ID: 23573867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
    Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A
    Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostatic fiducial markers implantation by transrectal ultrasound for adaptive image guided radiotherapy in localized cancer: 7-years experience.
    Lacetera V; Cardinali M; Mantello G; Fenu F; Sbrollini G; Tombolini F; Conti A; Maggi S; Muzzonigro G; Galosi AB
    Arch Ital Urol Androl; 2014 Dec; 86(4):349-52. PubMed ID: 25641469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer.
    Vesprini D; Catton C; Jacks L; Lockwood G; Rosewall T; Bayley A; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Nichol A; Skala M; Warde P; Bristow RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):608-16. PubMed ID: 22099034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
    Lawton CA; DeSilvio M; Lee WR; Gomella L; Grignon D; Gillin M; Morton G; Pisansky T; Sandler H
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):39-47. PubMed ID: 17084551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ; Weltman E; Hanriot RM; Luz FP; Cecílio PJ; da Cruz JC; Moreira FR; Santos AS; Martins LC; Nadalin W
    Radiat Oncol; 2007 Jan; 2():6. PubMed ID: 17224072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EUS-guided fiducial placement before targeted radiation therapy for prostate cancer.
    Yang J; Abdel-Wahab M; Ribeiro A
    Gastrointest Endosc; 2009 Sep; 70(3):579-83. PubMed ID: 19560140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.